Sunset Island Group, Inc.
SIGO
Other OTC0.00
USD
- -
- -
CIK
0001689066
ISIN
US8677442035
CUSIP
867744203
Return %
Stock
S&P500
1Y
0.00
18.86
3Y
-90.00
64.57
5Y
-99.94
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lori Livacich
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 20420 Spence Road Salinas CA United States of America 93908
- IPO Date
- Feb 2, 2017
- CIK
- 0001689066
- Website
- sunsetislandgroup.com
- Similar Companies
- Business
- Sunset Island Group, Inc. engages primarily in the cultivation and production of medical cannabis through its subsidiary, VBF Brands, operating in California, United States. The company’s core products include disease-free cannabis clones, cultivated in state-of-the-art greenhouse facilities, nursery operations, distribution, manufacturing, and cultivation of cannabis strains tailored to strong market demand. Additionally, it provides consulting services to clients operating within the medical marijuana industry. Founded in 2005 and headquartered in San Clemente, California, Sunset Island Group targets medical cannabis markets with a focus on superior genetics and advanced propagation technology. In recent major developments, Sunset Island Group executed a strategic expansion through the acquisition of Calamus Brands. This acquisition allows the company to significantly increase its operational footprint to 205,000 square feet, including greenhouse space usage for nursery growth—an expansion from the previous 10,000 square feet to an initial 35,000 square feet licensed for nursery operation. The company has emphasized a debt-minimization strategy throughout this expansion, aiming to maintain minimal liabilities while increasing production capacity to millions of cannabis plants annually. This expansion supports the company’s mission to enhance supply capabilities and introduce new products aligned with evolving market demands. Sunset Island Group operates mainly within the specialty pharmaceutical and healthcare sectors focused on cannabis-based products. It targets medical cannabis users, cultivators, and related businesses within California’s regulated cannabis market. The company’s recent operational and strategic moves underscore a commitment to large-scale cultivation and advancing nursery production technology to meet medical cannabis demand efficiently, positioning itself as a growing player in the US cannabis industry landscape. This includes the provision of sustainable, high-quality cannabis plant clones to medical marijuana operators, alongside consulting for industry compliance and growth strategies. Sunset Island Group remains a small-cap enterprise with a concentrated focus on cannabis cultivation and related services, sustaining its core operations and growth from its California base since its incorporation. Its ongoing expansion signifies a critical pivot to broaden production capacity and market presence through acquisitions and operational enhancements within this niche pharmaceutical cultivation sector. This summary provides a comprehensive view of Sunset Island Group’s product offerings and recent business expansions based on the latest publicly available information as of late 2025.